Evidence map›Paper›PMID 40259909›Full record

ArticleEcancermedicalscience2025

Effect on cardiovascular outcome of sodium-glucose co-transporter-2 (SGLT2) inhibitors among cancer patients treated with anthracycline: a systematic review and meta-analysis.

Chalothorn Wannaphut, Phuuwadith Wattanachayakul, Sakditad Saowapa, Ben Ponvilawan, Manasawee Tanariyakul, Jakrin Kewcharoen, Pitchaporn Yingchoncharoen, Thanathip Suenghataiphorn, Noppawit Aiumtrakul, Jared Acoba

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chalothorn WannaphutDepartment of Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI, USA.
Phuuwadith WattanachayakulDepartment of Medicine, Albert Einstein Healthcare Network, Philadelphia, PA, USA.
Sakditad SaowapaDepartment of Internal Medicine, Texas Tech Health Science Center, Lubbock, TX, USA.
Ben PonvilawanDepartment of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.
Manasawee TanariyakulDepartment of Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI, USA.
Jakrin KewcharoenDivision of Cardiology, Department of Medicine, Loma Linda University Health, Loma Linda, CA, USA.
Pitchaporn YingchoncharoenDepartment of Internal Medicine, Texas Tech Health Science Center, Lubbock, TX, USA.
Thanathip SuenghataiphornFaculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Noppawit AiumtrakulDepartment of Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI, USA.
Jared AcobaUniversity of Hawai'i Cancer Center, Honolulu, HI, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/objectives: Sodium-glucose-co-transporter-2 (SGLT2) inhibitors have shown benefit in reducing cardiovascular disease outcomes in diabetes patients. Anthracycline therapy is associated with a risk of cardiomyopathy. However, the impact of SGLT2 inhibitors in the prevention of cardiomyopathy and heart failure in cancer patients undergoing anthracycline treatment remains unclear. Thus, we conducted a systematic review and meta-analysis to explore the effect of the prevention of cardiovascular outcomes in patients with cancer and diabetes who had received anthracycline therapy. Methods: We systematically reviewed Medline and EMBASE databases from inception to January 2024 for studies focusing on cancer patients with a history of anthracycline therapy. Eligible studies had to report relative risk (RR) with 95% confidence intervals (CIs) for the clinical endpoints of mortality outcomes and the risk of heart failure exacerbation, comparing cohorts with and without SGLT2 inhibitor use. Results: Our study included four retrospective cohort studies in the meta-analysis ( Conclusion: Our study found that anthracycline-treated cancer patients using SGLT2 inhibitors experienced lower all-cause mortality compared to the control group. A randomised clinical trial is necessary to further elucidate these findings.

Indexed as

anthracyclinecancercardiovascular outcomesmeta-analysisSGLT2 inhibitors

Identifiers

PMID40259909
PMCPMC12010125

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.